Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice-Reference-Cited by-同舟云学术

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Published:2010-06-22 Issue:6 Volume:16 Page:866-877
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

OLDENBURG J.,GOUDEMAND J.,VALENTINO L.,RICHARDS M.,LUU H.,KRIUKOV A.,GAJEK H.,SPOTTS G.,EWENSTEIN B.

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02332.x/fullpdf

Reference54 articles.

1. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions;Clark;Curr Drug Saf,2006

2. Post-market approval surveillance: a call for a more integrated and comprehensive approach;Mehran;Circulation,2004

3. Post-marketing surveillance of drugs. The spontaneous reporting scheme: role of the Adverse Drug Reactions Advisory Committee;Roeser;Med J Aust,1990

4. The rationale for a post-marketing surveillance;Westerholm;Hum Reprod,1987

5. Guidance for Industry Reports on the Status of Postmarketing Study Commitments - Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 2006 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM080569.pdf

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin;International Journal of Environmental Research and Public Health;2020-12-30

2. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting;Annals of Hematology;2020-09-11

3. Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A;Haemophilia;2020-04-27

4. Unusual olecranon mass with ulnar nerve compressive neuropathy caused by a haemophilic pseudotumour;BMJ Case Reports;2019-09

5. Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan;International Journal of Hematology;2019-01-02